المؤلفون: V. Grünwald, T. Powles, E. Kopyltsov, V. Kozlov, T. Alonso-Gordoa, M. Eto, T. Hutson, R. Motzer, E. Winquist, P. Maroto, B. Keam, G. Procopio, S. Wong, B. Melichar, F. Rolland, M. Oya, K. Rodriguez-Lopez, K. Saito, J. McKenzie, C. Porta, Е. Kopyltsov, М. Eto

المساهمون: Данное исследование было спонсировано Eisai Inc., Натли, Нью-Джерси, США и Merck Sharp & Dohme LLC – дочерняя компания Merck & Co., Inc., Рауэй, Нью-Джерси, США. Помощь в написании статьи финансировалась Eisai Inc., Натли, Нью-Джерси, США и Merck Sharp & Dohme LLC – дочерней компанией Merck & Co., Inc., Рауэй, Нью-Джерси, США. Пациентам, получавшим лечение в Мемориальном онкологическом центре им. Слоуна–Кеттеринга, частично оказывалась поддержка за счет гранта поддержки Мемориального онкологического центра им. Слоуна–Кеттеринга/Основного гранта (P30 CA008748)

المصدر: Cancer Urology; Том 19, № 4 (2023); 32-43 ; Онкоурология; Том 19, № 4 (2023); 32-43 ; 1996-1812 ; 1726-9776

مصطلحات موضوعية: почечно-клеточный рак, pembrolizumab, sunitinib, depth of response, renal cell carcinoma, пембролизумаб, сунитиниб, степень ответа

وصف الملف: application/pdf

العلاقة: https://oncourology.abvpress.ru/oncur/article/view/1786/1493Test; National Cancer Institute. Surveillance, Epidemiology, and End Results Program (SEER). Cancer stat facts: kidney and renal pelvis cancer. Available at: https://seer.cancer.gov/statfacts/html/kidrp.htmlTest.; International Agency for Research on Cancer (IARC). GLOBOCAN 2020. Cancer Today. Available at: https://gco.iarc.fr/today/homeTest.; Padala S.A., Barsouk A., Thandra K.C. et al. Epidemiology of renal cell carcinoma. World J Oncol 2020;11(3):79–87. DOI:10.14740/wjon1279; Li P., Wong Y.N., Armstrong K. et al. Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy eras. Cancer Med 2016;5(2):169–81. DOI:10.1002/cam4.574; Choueiri T.K., Motzer R.J. Systemic therapy for metastatic renalcell carcinoma. N Engl J Med 2017;376(4):354–66. DOI:10.1056/NEJMra1601333; Choueiri T.K., Kaelin Jr W.G. Targeting the HIF2-VEGF axis in renal cell carcinoma. Nat Med 2020;26(10):1519–30. DOI:10.1038/s41591-020-1093-z; Choueiri T.K., Powles T., Burotto M. et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2021;384(9):829–41. DOI:10.1056/NEJMoa2026982; Motzer R.J., Tannir N.M., McDermott D.F. et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 2018;378(14):1277–90. DOI:10.1056/NEJMoa1712126; Motzer R., Alekseev B., Rha S.Y. et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med 2021;384(14):1289–300. DOI:10.1056/NEJMoa2035716; Motzer R.J., Penkov K., Haanen J. et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019;380(12):1103–15. DOI:10.1056/NEJMoa1816047; Rini B.I., Plimack E.R., Stus V. et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019;380(12):1116–27. DOI:10.1056/NEJMoa1816714; Rassy E., Flippot R., Albiges L. Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma. Ther Adv Med Oncol 2020;12:1758835920907504. DOI:10.1177/1758835920907504; National Comprehensive Cancer Network clinical practice guidelines in oncology (NCCN Guidelines). Kidney cancer. Version 3.2022. Available at: http://www.nccn.org/professionals/physician_gls/PDF/kidney.pdfTest.; Bedke J., Albiges L., Capitanio U. et al. Updated European Association of Urology guidelines on renal cell carcinoma: nivolumab plus cabozantinib joins immune checkpoint inhibition combination therapies for treatment-naïve metastatic clear-cell renal cell carcinoma. Eur Urol 2021;79(3):339–42. DOI:10.1016/j.eururo.2020.12.005; Powles T., Albiges L., Bex A. et al. ESMO clinical practice guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma. Ann Oncol 2021;32(12):1511–9. DOI:10.1016/j.annonc.2021.09.014; Motzer R.J., Hutson T.E., Glen H. et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol 2015;16(15):1473–82. DOI:10.1016/S1470-2045(15)00290-9; Pal S.K., Puente J., Heng D.Y.C. et al. Phase II trial of lenvatinib (LEN) at two starting doses + everolimus (EVE) in patients (pts) with renal cell carcinoma (RCC): results by independent imaging review (IIR) and prior immune checkpoint inhibition (ICI) [abstract]. J Clin Oncol 2021;39(6 Suppl):307.; Larkin J.M.G., Tykodi S.S., Donskov F. et al. First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): updated follow-up for KEYNOTE-427 cohort A. Ann Oncol 2019;30(Suppl 5):v381–2, Abstract 949P.; Lee J.L., Ziobro M., Gafanov R. et al. KEYNOTE-427 cohort B: first-line pembrolizumab (pembro) monotherapy for advanced nonclear cell renal cell carcinoma (NCC-RCC). J Clin Oncol 2019;37(15 Suppl):4569.; Lee C.H., Shah A.Y., Rasco D. et al. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (study 111/KEYNOTE-146): a phase 1b/2 study. Lancet Oncol 2021;22(7):946–58. DOI:10.1016/S1470-2045(21)00241-2; Grünwald V., McKay R.R., Krajewski K.M. et al. Depth of remission is a prognostic factor for survival in patients with metastatic renal cell carcinoma. Eur Urol 2015;67(5):952–8. DOI:10.1016/j.eururo.2014.12.036; Motzer R., Porta C., Alekseev B. et al. Health-related quality of life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib: a randomized phase 3 study (CLEAR trial). Lancet Oncol 2022;23(6):768–80. DOI:10.1016/S1470-2045(22)00212-1; Powles T., Plimack E.R., Soulières D. et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended followup from a randomised, open-label, phase 3 trial. Lancet Oncol 2020;21(12):1563–73. DOI:10.1016/S1470-2045(20)30436-8; Motzer R.J., Escudier B., McDermott D.F. et al. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. J Immunother Cancer 2020;8(2):e000891. DOI:10.1136/jitc-2020-000891; Rini B.I., Plimack E.R., Stus V. et al. Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): results from 42-month follow-up of KEYNOTE-426. J Clin Oncol 2021;39(15 Suppl):4500.; Haanen J.B.A.G., Larkin J., Choueiri T.K. et al. Efficacy of avelumabaxitinib (AAx) versus sunitinib (S) by IMDC risk group in advanced renal cell carcinoma (aRCC): extended follow-up results from JAVELIN Renal 101. J Clin Oncol 2021;39(15 Suppl):4574.; Albiges L., Tannir N.M., Burotto M. et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open 2020;5(6):e001079. DOI:10.1136/esmoopen-2020-001079; Leary A., Larkin J.M., Pickering L.M. Cytokine therapy for renal cell cancer: the evolving role of immunomodulation. Therapy 2011;8:347–58.; Fisher R.I., Rosenberg S.A., Fyfe G. Long-term survival update for highdose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 2000;6(Suppl 1):S55–7.; https://oncourology.abvpress.ru/oncur/article/view/1786Test

الإتاحة: https://doi.org/10.17650/1726-9776-2023-19-4-32-43Test
https://doi.org/10.14740/wjon1279Test
https://doi.org/10.1002/cam4.574Test
https://doi.org/10.1056/NEJMra1601333Test
https://doi.org/10.1038/s41591-020-1093-zTest
https://doi.org/10.1056/NEJMoa2026982Test
https://doi.org/10.1056/NEJMoa1712126Test
https://doi.org/10.1056/NEJMoa2035716Test
https://doi.org/10.1056/NEJMoa1816047Test
https://doi.org/10.1056/NEJMoa1816714Test

المؤلفون: Garcia-Carbonero, R., Cote, G.M., Le Cesne, A., Anton-Pascual, B., Gordoa, T. Alonso, Gonzalez, A. Falcon, Torralvo, A. Gil, Martinez, S., Siguero, M., Cullell, M., Fudio, S., Zeaiter, A., Cerrillo, J. Molina

المصدر: ESMO Open ; volume 9, page 102416 ; ISSN 2059-7029

مصطلحات موضوعية: Cancer Research, Oncology

الإتاحة: https://doi.org/10.1016/j.esmoop.2024.102416Test
https://api.elsevier.com/content/article/PII:S2059702924001844?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S2059702924001844?httpAccept=text/plainTest

المؤلفون: J. Capdevila, J. Hernando, A. Teule, C. Lopez, R. Garcia-Carbonero, M. Benavent, A. Custodio, A. Garcia-Alvarez, A. Cubillo, V. Alonso, A. Carmona-Bayonas, T. Alonso-Gordoa, G. Crespo, P. Jimenez-Fonseca, M. Blanco, A. Viudez, A. La Casta, I. Sevilla, A. Segura, M. Llanos, S. Landolfi, P. Nuciforo, J. L. Manzano

المصدر: Nature Communications, Vol 14, Iss 1, Pp 1-8 (2023)

مصطلحات موضوعية: Science

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2041-1723Test

الوصول الحر: https://doaj.org/article/4657999dcefc4e29962cf3727fc74593Test

المؤلفون: C. Castán-Fernández, G. Marcos-Robredo, M. P. Castro-García, M. A. Rey-Ronco, T. Alonso-Sánchez

المصدر: Inventions; Volume 8; Issue 1; Pages: 30

مصطلحات موضوعية: thermal conductivity measurement, geothermal backfill materials, transient Hot Wire (THW), Infinite Linear Source (ILS), Arduino

وصف الملف: application/pdf

العلاقة: Inventions and innovation in Energy and Thermal/Fluidic Science; https://dx.doi.org/10.3390/inventions8010030Test

الإتاحة: https://doi.org/10.3390/inventions8010030Test

المؤلفون: Huerta T. Alonso, Hernández Z. Julián

المصدر: Observador del Conocimiento Vol. 3 Nº 3 agosto 2016(2343-6212) 92-100

مصطلحات موضوعية: Aplicación web, censo comunitario, consejo comunal, Web application, community census, community council

العلاقة: https://zenodo.org/communities/oc20Test; https://zenodo.org/record/6246987Test; https://doi.org/10.5281/zenodo.6246987Test; oai:zenodo.org:6246987

الإتاحة: https://doi.org/10.5281/zenodo.6246987Test
https://doi.org/10.5281/zenodo.6246986Test
https://zenodo.org/record/6246987Test

المؤلفون: M. Araujo-Castro, E. Pascual-Corrales, J. Lorca Álvaro, C. Mínguez Ojeda, H. Pian, I. Ruz-Caracuel, A. Sanjuanbenito Dehesa, A.B. Serrano Romero, T. Alonso-Gordoa, J. Molina-Cerrillo, V. Gómez Dos Santos

المصدر: Actas Urológicas Españolas (English Edition). 47:68-77

مصطلحات موضوعية: General Medicine

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::56465ebd6229b2d4ab619fcb19d289a5Test
https://doi.org/10.1016/j.acuroe.2022.08.008Test

المؤلفون: M. Araujo-Castro, E. Pascual-Corrales, J. Lorca Álvaro, C. Mínguez Ojeda, H. Pian, I. Ruz-Caracuel, A. Sanjuanbenito Dehesa, A.B. Serrano Romero, T. Alonso-Gordoa, J. Molina-Cerrillo, V. Gómez Dos Santos

المصدر: Actas Urológicas Españolas. 47:68-77

مصطلحات موضوعية: Urology

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::1ab45dabef250383805f4e27d6504c91Test
https://doi.org/10.1016/j.acuro.2022.05.008Test

المؤلفون: Muñoz, F. Longo, Salgado, A. Cortés, Domingo, J.J. Serrano, Casado, J.L., Vallejo, A., Serrano, C. Saavedra, Pérez, J. Chamorro, Rodríguez, D.I. Rosero, Velasco, H., Martin, A., Soria, A., Garcia, M.E. Olmedo, Rueda, A. Gomez, Lage, Y., Gordoa, T. Alonso, Cerrillo, J. Molina, Borau, P. Gajate, Martínez del Frade, Í., Lopez, P. Garrido, Carrato-Mena, A.

المصدر: Annals of Oncology ; volume 32, page S1424 ; ISSN 0923-7534

مصطلحات موضوعية: Oncology, Hematology

الإتاحة: https://doi.org/10.1016/j.annonc.2021.10.130Test
https://api.elsevier.com/content/article/PII:S0923753421046664?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0923753421046664?httpAccept=text/plainTest

المؤلفون: Niels H Birkebaek, Clemens Kamrath, Julia M Grimsmann, Karin Aakesson, Valentino Cherubini, Klemen Dovc, Carine de Beaufort, Guy T Alonso, John W Gregory, Mary White, Torild Skrivarhaug, Zdenek Sumnik, Craig Jefferies, Thomas Hörtenhuber, Aveni Haynes, Martin De Bock, Jannet Svensson, Justin T Warner, Osman Gani, Rosaria Gesuita, Riccardo Schiaffini, Ragnar Hanas, Arleta Rewers, Alexander J Eckert, Reinhard W Holl, Ondrej Cinek

المصدر: Birkebaek, N H, Kamrath, C, Grimsmann, J M, Aakesson, K, Cherubini, V, Dovc, K, de Beaufort, C, Alonso, G T, Gregory, J W, White, M, Skrivarhaug, T, Sumnik, Z, Jefferies, C, Hörtenhuber, T, Haynes, A, De Bock, M, Svensson, J, Warner, J T, Gani, O, Gesuita, R, Schiaffini, R, Hanas, R, Rewers, A, Eckert, A J, Holl, R W & Cinek, O 2022, ' Impact of the COVID-19 pandemic on long-term trends in the prevalence of diabetic ketoacidosis at diagnosis of paediatric type 1 diabetes : an international multicentre study based on data from 13 national diabetes registries ', The Lancet Diabetes and Endocrinology, vol. 10, no. 11, pp. 786-794 . https://doi.org/10.1016/S2213-8587Test(22)00246-7

مصطلحات موضوعية: Diabetes Mellitus, Type 1, Endocrinology, Adolescent, Endocrinology, Diabetes and Metabolism, Prevalence, Internal Medicine, Humans, COVID-19, Registries, Child, Pandemics, Diabetic Ketoacidosis

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9a5c31f46966c22e2a87f6a3751d284Test
https://doi.org/10.1016/s2213-8587Test(22)00246-7

المؤلفون: A. Ferrer Martínez, M. J. Castillo Fe, M. T. Alonso García, S. Villar Riu, O. Bonachia Naranjo, C. Sánchez Cabezudo, A. Marcos Herrero, J. L. Porrero Carro

المصدر: Hernia.

مصطلحات موضوعية: Surgery

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::5e27895265d99d7fdbe852294c106d4fTest
https://doi.org/10.1007/s10029-023-02766-3Test